Filing Flows

Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Next earnings date

NewAmsterdam Pharma Co N.V. (NAMS) earnings: beat the estimate

NewAmsterdam Pharma Co N.V. (NAMS) reported on Nov 4, 2026 and beat the EPS estimate: −$0.12 against −$0.44 (+71.4%). Revenue was $19.2M for Q3 2026, 55× year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+71.4% vs estimate
Beat rate40%

The last report

NewAmsterdam Pharma Co N.V. reported revenue of $19.2M for the third quarter 2026 (55× Y/Y), net loss $17.4M. How it makes money → · Every quarter →

NewAmsterdam Pharma Co N.V.: EPS against the estimate, last 5 reportsNewAmsterdam Pharma Co N.V.: EPS against the estimate, last 5 reportsEstimateReported−$0.34−$0.53Nov 25−$0.37−$0.53Feb 26−$0.41−$0.34May 26−$0.43−$0.45Aug 26−$0.44−$0.12Nov 26
Latest (Nov 26): Estimate −$0.44, Reported −$0.12.

NewAmsterdam Pharma Co N.V.'s latest quarter

NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.

Questions

Did NewAmsterdam Pharma Co N.V. beat earnings?

NewAmsterdam Pharma Co N.V.

When does NAMS report earnings?

The next date is not set yet.

Does NewAmsterdam Pharma Co N.V. usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.